JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matsumoto, K.
Right arrow Articles by Nakamura, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsumoto, K.
Right arrow Articles by Nakamura, T.

J Biol Chem, Vol. 273, Issue 36, 22913-22920, September 4, 1998


Cooperative Interaction between alpha - and beta -Chains of Hepatocyte Growth Factor on c-Met Receptor Confers Ligand-induced Receptor Tyrosine Phosphorylation and Multiple Biological Responses*

Kunio Matsumoto, Hirofumi Kataoka, Kazuhiko Date, and Toshikazu NakamuraDagger

From the Division of Biochemistry, Biomedical Research Center, Osaka University Medical School, Suita, Osaka 565-0871, Japan

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Hepatocyte growth factor (HGF) is a heterodimeric molecule composed of the alpha -chain containing the N-terminal hairpin domain, four kringle domains, and the serine protease-like beta -chain. We prepared HGF/NK4 and HGF/beta from the entire HGF after single-cut digestion with elastase. HGF/NK4 contains the N-terminal hairpin and four kringle domains, while HGF/beta is composed of the C-terminal 16 amino acids of the alpha -chain and the entire beta -chain, linked by a disulfide bridge. HGF/NK4 competitively inhibited the binding of 125I-HGF to the receptor, and affinity cross-linking analysis indicated that HGF/NK4 alone can bind to the c-Met receptor. In contrast, HGF/beta alone did not competitively inhibit the binding of 125I-HGF to the receptor and did not bind to the c-Met/HGF receptor. Scatchard analysis and affinity cross-linking experiments indicated that HGF/beta specifically binds to c-Met in the presence of HGF/NK4 but not HGF/NK2. Neither HGF/NK4 nor HGF/beta alone induced mitogenic, motogenic (cell scattering), and morphogenic (induction of branching tubulogenesis) responses; however, HGF/beta did induce these biological responses in the presence of HGF/NK4. Consistent with these results, although neither HGF/NK4 alone nor HGF/beta alone induced tyrosine phosphorylation of the c-Met/HGF receptor, HGF/beta induced tyrosine phosphorylation of the receptor when c-Met/HGF receptor was occupied by HGF/NK4. These results indicate that HGF/beta binds to the c-Met/HGF receptor that is occupied by HGF/NK4 and induces receptor tyrosine phosphorylation and the subsequent biological activities of HGF. We propose that there exists a unique cooperative interaction between alpha - and beta -chains, this interaction leading to beta -chain-dependent receptor tyrosine phosphorylation and subsequent biological responses.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Coupling between hepatocyte growth factor (HGF)1 and its receptor, c-met protooncogene product of heterodimeric tyrosine kinase integrates mitogenic, motogenic, and morphogenic activities in a wide variety of cells (1-3). Most epithelial cells and several types of mesenchymal cells are target cells of HGF (1-3). Physiologically, HGF is a potent "trophic" factor for regeneration of organs (3), and it possesses potent angiogenic activity (4, 5). In addition to roles in epithelial and endothelial tissues, HGF is an important regulator in the maintenance of stromal tissues and cells, including bone formation (6), chondrogenesis (7), and hematopoiesis (8, 9). The particular importance of HGF and c-Met/HGF receptor in developmental processes was demonstrated by targeted mutation of HGF or c-Met/HGF receptor gene (10-13). HGF is essential for the development of the liver and placenta, and it supports migration of myogenic precursor cells. In vitro analysis also showed that HGF supports morphogenic events during development of the kidney, mammary gland, lung, and tooth (1-3, 14-16). Together with a preferential expression of HGF in mesenchymal (or stromal) tissue (17, 18), HGF is considered to be a mesenchymal-derived mediator in epithelial-mesenchymal (or -stromal) interactions during organogenesis and organ regeneration.

Biologically active HGF is a disulfide-linked heterodimer composed of a 69-kDa alpha -chain and a 34-kDa beta -chain (19-21). The alpha -chain contains the N-terminal hairpin domain and subsequently four homologous kringle domains, while the beta -chain contains a serine protease-like domain (22). To address the specific function of each subunit in the HGF molecule, variously mutated variant HGFs were tested for biological activities and receptor binding. A small molecule consisting of the N-terminal hairpin domain, the first kringle domain (K1), and the second kringle domain (K2), designated HGF/NK2 exists as a naturally biosynthesized variant form, and HGF/NK2 can bind the c-Met/HGF receptor (23-26). Importantly, HGF/NK2 shows motogenic activity, i.e. enhancement of cell motility, but lacks mitogenic activity (23, 25-27). Thus, HGF/NK2, capable of receptor binding, is an antagonist for the mitogenic activity of HGF (23), yet retains selective agonistic activity in terms of cell motility (25, 27). Subsequently, Lokker and Godowski (28) showed that HGF/NK1, composed of the N-terminal hairpin domain and K1, can bind to the c-Met/HGF receptor, while Cioce et al. (29) reported that HGF/NK1 is a naturally occurring variant with partial agonistic or antagonistic activity in a different assay system. On the other hand, the beta -chain alone cannot bind to the c-Met/HGF receptor and has none of the biological activities of HGF (25, 26, 30, 31). Nevertheless, deletion of the beta -chain in HGF results in loss of biological activities of HGF, even though the alpha -chain alone can bind to the c-Met/HGF receptor (25, 30, 31).

Previous studies clarified the specific function of the N-terminal half of the alpha -chain (HGF/NK2), as a receptor-binding motif, as well as a partial agonist in terms of motogenic activity. Thus, biological function of the beta -chain remained to be specified. We recently obtained the antagonist for HGF, termed "HGF/NK4" (32). HGF/NK4 contains the N-terminal hairpin structure and four kringle domains. We have now obtained evidence which supports the proposal that the beta -chain can bind to the c-Met/HGF receptor which is specifically occupied with HGF/NK4, and that this cooperative binding induces receptor tyrosine phosphorylation of c-Met, leading to mitogenic, motogenic, and morphogenic responses. The alpha -chain of HGF can bind to the c-Met/HGF receptor, but the optimum activation of c-Met/HGF receptor for the transduction of multiple biological activities of HGF depends on the beta -chain.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials-- Human recombinant HGF was purified from the conditioned medium of Chinese hamster ovary cells transfected with human HGF cDNA (22, 33). HGF used in the present study was of the 5-amino acid-deleted type (33). The purity of HGF exceed 98%, as determined by SDS-PAGE and protein staining. Anti-phosphotyrosine monoclonal antibody (PY-20) was obtained from Chemicon International Inc. (Temecula, CA) and anti-c-Met polyclonal antibody (C-12) from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Pyroglutamate aminopeptidase was obtained from TAKARA Co. Ltd. (Otsu, Japan). Monoclonal antibody against the alpha -chain of HGF was prepared as described elsewhere (34).

Preparation of HGF/NK4, HGF/beta , and HGF/NK2-- Human recombinant HGF was digested with pancreatic elastase (Sigma), and the digested material was applied onto µBondapak C4 reverse-phase HPLC column and adsorbed materials were eluted with a gradient of acetonitrile containing 0.05% (v/v) trifluoroacetic acid (32). HGF/beta was further purified using a Hi-Trap heparin column (Amersham Pharmacia Biotech, Uppsala). The preparation of HGF/beta was rechromatographed on C4 reverse-phase HPLC, as described above. The final preparation of HGF/beta used in this study contained 0.003% (in molar ratio) of intact HGF, as detected by enzyme-linked immunosorbent assay (32). Biochemical analysis indicated that HGF/NK4 is composed of the N-terminal hairpin and subsequent four kringle domains, which corresponds to the alpha -chain deleted with C-terminal 16 amino acids, while HGF/beta is composed of the C-terminal 16 amino acids of the alpha -chain and the entire beta -chain, linked by a disulfide bridge between Cys487 and Cys604 (Fig. 1A).

HGF/NK2 was produced by transient expression in COS-7 cells, using the expression vector pCDM containing cDNA, which corresponds to the sequence of human HGF/NK2, as described elsewhere (23). HGF/NK2 was purified from the serum-free conditioned medium using a Hi-Trap heparin column (Amersham Pharmacia Biotech). The recombinant HGF/NK2 showed an apparent molecular mass of 28 kDa in SDS-PAGE and following Western immunoblotting, under reducing condition (not shown). SDS-PAGE was done using a 4-20% or 2-15% gradient gel, and proteins were visualized by silver staining (Wako Pure Chemical, Osaka).

Cell Culture and Measurement of DNA Synthesis-- MDCK (clone 3B) renal epithelial cells, a kind gift from Dr. R. Montesano (University of Geneva) were cultured in DMEM containing 10% fetal calf serum. HuCC-T1 human cholangiocarcinoma and A549 human lung adenocarcinoma cells were obtained from the Japanese Cancer Research Resources Bank and cultured in DMEM containing 10% fetal calf serum. For migration assay, MDCK cells were seeded on a 48-well plate at a density of 2.5 × 103 cells/well in DMEM containing 10% fetal calf serum, with or without test samples. The cells were cultured for 20 h, then photographed. For three-dimensional culture in collagen gels, MDCK cells were harvested using trypsin-EDTA solution, suspended in ice-cold 0.2% collagen solution (Nitta Gelatin, Tokyo) at a density of 104 cells/ml, and 500-µl aliquots were added to wells of a 16-mm width (Nunc, Roskilde, Denmark). After the collagen solution gelled, 500 µl of culture medium containing HGF, HGF/NK4, and/or HGF/beta were added. Culture medium was changed every 3 days.

Mitogenic activity of HGF, HGF/NK4, HGF/beta , or their combinations was measured using adult rat hepatocytes in primary culture, as described elsewhere (30). HGF, HGF/NK4, HGF/beta , HGF/NK2, or their combinations were added to cultures of hepatocytes, the culture was run for 20 h, and then pulse-labeled with 0.3 µCi/ml 125I-deoxyuridine for 6 h. The cells were washed twice with phosphate-buffered saline and once with trichloroacetic acid, then solubilized with M NaOH. Radioactivity of 125I-deoxyuridine incorporated into nuclei was measured using a gamma -counter.

Radiolabeled Ligand Binding Assay to the c-Met/HGF Receptor-- HGF, HGF/NK4, and HGF/beta were respectively radioiodinated by the chloramine-T method, as described elsewhere (32). The competitive binding assay was performed by incubating 60 pM 125I-HGF and various concentrations of unlabeled HGF, HGF/NK4, or HGF/beta , simultaneously with 50 µg of plasma membranes from rat livers at 12 °C for 1 h, in 0.1 ml of binding buffer (Hanks' solution containing 20 mM HEPES and 2 mg/ml bovine serum albumin, pH 7.0). Membranes were centrifuged at 12,000 × g for 10 min at 4 °C, resuspended with 10 µl of binding buffer and transferred to fresh tubes. 125I-HGF specifically bound to membranes was measured using a gamma -counter.

Concentration-dependent binding of radiolabeled ligand and Scatchard analysis were performed using HuCC-T1 cells, as described elsewhere (32). Briefly, the cells were cultured on a 24-well plate, and the cultures were washed once with the binding buffer and equilibrated in the same buffer for 30 min at 10 °C. Ice-cold binding buffer containing increasing concentrations of 125I-HGF or 125I-HGF/beta , with or without 100 times excess molar unlabeled HGF or HGF/beta , was added, and the preparation was incubated at 12 °C for 1 h. Cultures were washed three times with ice-cold binding buffer, and radiolabeled ligand bound to cells was measured. All binding experiments were done in quadruplicate.

Detection of Receptor Tyrosine Phosphorylation-- Subconfluent A549 cells were cultured in serum-free DMEM supplemented with 0.2% (w/v) bovine serum albumin for 20 h. The cells were treated with HGF, HGF/NK4, and/or HGF/beta , washed with phosphate-buffered saline containing 1 mM Na3VO4, and the cell lysate was centrifuged at 12,000 × g for 10 min, as described previously (32). The resultant supernatant was preadsorbed with protein A-Sepharose (Amersham Pharmacia Biotech) and centrifuged at 12,000 × g for 10 min. The supernatant was treated with anti-human c-Met antibody and protein A-Sepharose. Immunoprecipitated materials were washed with lysis buffer and solubilized with sample buffer for SDS-PAGE. The immunoprecipitates were separated by SDS-PAGE, electroblotted onto a polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA), and probed with anti-phosphotyrosine monoclonal antibody or anti-c-Met antibody. Proteins reacting with these antibodies were detected using ECL enhanced chemiluminescence (Amersham, Little Chalfont, UK).

Affinity Cross-linking-- HuCC-T1 cells cultured in a 90 mm dish were washed twice with ice-cold binding buffer consisting of Hanks' balanced salt solution containing 20 mM HEPES-NaOH (pH 7.0) and 0.2% (w/v) bovine serum albumin and incubated in the binding buffer for 30 min at 10 °C. The binding buffer was changed to fresh binding buffer, and the radiolabeled ligand was added. After 1 h of incubation at 10 °C, bis(sulfosuccinimidyl) suberate (Pierce) was added at the final concentration of 0.5 µM, and the cells were incubated 1 h at 4 °C. After cells had been washed twice with phosphate-buffered saline, the cells were lyzed and scraped into buffer composed of 20 mM Tris-HCl (pH 7.4), 10 mM EDTA, 150 mM NaCl, 5 µg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 0.5% Triton X-100. The cell suspension in a siliconized tube was centrifuged at 15,000 rpm for 10 min, and the supernatant was preadsorbed with 25 µl of protein A-Sepharose (Amersham Pharmacia Biotech) for 1 h at 4 °C. After centrifugation at 5,000 rpm for 5 min, the supernatant was treated with rabbit anti-c-Met antibody for 2 h at 4 °C, then 7.5 µl of protein A-Sepharose was added. The preparation was centrifuged, and the precipitated material was washed four times with lysis buffer and solubilized in the sample buffer for SDS-PAGE. The solubilized proteins were subjected to SDS-PAGE, using 2-15% gradient gel, and the gel was subjected to autoradiography.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Receptor Binding Ability of HGF/NK4 and HGF/beta -- To determine whether HGF/NK4 and HGF/beta can bind to the cell surface receptor, competitive binding analysis was carried out using 125I-HGF (Fig. 1B). Liver plasma membranes were incubated in the presence of 125I-HGF alone, or 125I-HGF plus various concentrations of unlabeled HGF, HGF/NK4, or HGF/beta . Addition of unlabeled HGF inhibited the specific binding of 125I-HGF to the plasma membranes, and 50% inhibition by unlabeled HGF was seen with 60 pM HGF; the dose being approximately equimolar to that of 125I-HGF.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 1.   Structural characterization of HGF/NK4 and HGF/beta (A) and displacement curve of 125I-HGF binding to liver plasma membranes by unlabeled HGF, HGF/NK4, or HGF/beta (B). Specific binding of 60 pM 125I-HGF to rat liver plasma membranes was measured in the presence of various concentrations of unlabeled HGF, HGF/NK4, or HGF/beta . Each value represents the mean of quadruplicate measurements.

Addition of HGF/NK4 also inhibited the binding of 125I-HGF, and the inhibition by 50% was seen with 600 pM HGF/NK4; the concentration was 10-fold higher than that of HGF. In contrast, the addition of HGF/beta did not inhibit the binding of 125I-HGF, at least up to 30 nM, the maximal concentration tested here. Therefore, HGF/NK4 seems to bind to the c-Met/HGF receptor with a 10-fold lower affinity than that of the native HGF; however, HGF/beta does not bind to the receptor.

Mitogenic Activity of HGF/NK4 and HGF/beta -- We next examined the mitogenic activity of HGF/NK4 and HGF/beta , using adult rat hepatocytes in primary culture (Fig. 2A). Addition of 100 pM HGF potently stimulated DNA synthesis to over 10-fold higher levels. In contrast, addition of HGF/beta alone up to 30 nM had no apparent effect on DNA synthesis. This result is consistent with the finding that HGF/beta alone cannot bind to the c-Met/HGF receptor. On the other hand, 1.5 nM HGF/NK4 alone had no evident effect on DNA synthesis, even though HGF/NK4 at this concentration seems to occupy most of the c-Met/HGF receptor. However, it is noteworthy that the addition of HGF/beta in the presence of 1.5 nM HGF/NK4 dose-dependently induced mitogenic responses in hepatocytes, and the maximal stimulatory effect was seen at 30 nM HGF/beta and was 50-60% of that of HGF.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 2.   Mitogenic activity of HGF/NK4, HGF/NK2, and HGF/beta , and their combinations in primary cultured hepatocytes. A, mitogenic activity of HGF/NK4, HGF/beta , and their combinations. B, mitogenic activity of HGF/NK2 and its combinations with HGF/beta . Mitogenic activity was determined by measuring DNA synthesis of rat hepatocytes in primary culture.

Previous studies showed that the two-kringle variant form, HGF/NK2 can bind to the c-Met/HGF receptor and has motogenic (enhancement of cell motility) but not mitogenic activity (23, 25-27). We then asked whether the combination of HGF/NK2 and HGF/beta would elicit mitogenic activity, as seen in the combination of HGF/NK4 and HGF/beta (Fig. 2B). Although HGF/NK4 plus HGF/beta , as well as native HGF, stimulated DNA synthesis in hepatocytes, HGF/NK2 alone or 30 nM HGF/beta plus HGF/NK2 did not stimulate DNA synthesis.

Motogenic and Morphogenic Activities of HGF/NK4 and HGF/beta -- When HGF was added to the monolayer culture of MDCK cells, HGF enhanced their motility and induced scattering of the cells (Fig. 3). Neither HGF/NK4 (1.5 nM) alone nor HGF/beta (30 nM) alone induced scattering of the MDCK cells. However, when HGF/beta was added to the culture in the presence of HGF/NK4, HGF/beta dose-dependently induced scattering of the cells. The cell scattering seen with 1.5 nM HGF/NK4 plus 30 nM HGF/beta was comparable to that seen with 100 pM HGF. Consistent with previous reports (23, 25-27), the addition of HGF/NK2 alone (3.3 nM) induced scattering of MDCK cells (not shown). On the other hand, Hartmann et al. (25) previously showed that the alpha -chain of HGF has weak motogenic activity. A discrepancy regarding the biological activity between HGF/NK4 and the alpha -chain may be attributable to the structural difference between HGF/NK4 and the alpha -chain; HGF/NK4 lacks C-terminal 16 amino acids of the alpha -chain (Fig. 1A). Importantly, the C-terminal 16-amino acid fragment contains a cysteine residue involved in a disulfide bond between the alpha - and beta -chain of HGF. When the entire alpha -chain alone was expressed in mammalian cells, the alpha -chain formed, at least, a homodimer, presumably through a disulfide bond between C-terminal-free cysteines. Moreover, the recombinant alpha -chain preparation showed weak motogenic activity.2 Covalently dimerized alpha -chain may induce receptor dimerization and thus allow low level signaling, leading to cell scattering.


View larger version (181K):
[in this window]
[in a new window]
 
Fig. 3.   Motogenic activity of HGF/NK4, HGF/beta , and their combinations. Motogenic activity was measured by evaluating cell scattering in MDCK cells in monolayer culture. MDCK cells were cultured for 24 h in the absence (A) or presence of 0.1 nM HGF (B), 1.5 nM HGF/NK4 (C), 30 nM HGF/beta (D), 1.5 nM HGF/NK4 plus 3 nM HGF/beta (E), or 1.5 nM HGF/NK4 plus 30 nM HGF/beta (F).

We also asked whether HGF/NK4 and HGF/beta have morphogenic activity (Fig. 4). When MDCK cells were grown in a collagen gel matrix, they form spherical cysts, but when grown in the presence of HGF, branching tubulogenesis occurred. Neither HGF/NK4 alone, nor HGF/beta induced branching tubular structures in the MDCK cells; however, the addition of HGF/beta in the presence of 1.5 nM HGF/NK4 did induce branching tubulogenesis, as seen with the native HGF. These results indicate that the combination of HGF/NK4 and HGF/beta elicits mitogenic, motogenic, and morphogenic activities, all typical for multiple biological activities of HGF, although neither HGF/NK4 alone nor HGF/beta alone has biological activities.


View larger version (152K):
[in this window]
[in a new window]
 
Fig. 4.   Morphogenic activity of HGF/NK4, HGF/beta , and their combinations. Morphogenic activity was analyzed by evaluating the formation of branching tubulogenesis in MDCK cells grown in a collagen gel matrix for 6 days in the absence (A and G) or presence of 0.1 nM HGF (B), 1.5 nM HGF/NK4 (C), 30 nM HGF/beta (D), 1.5 nM HGF/NK4 plus 3 nM HGF/beta (E), or 1.5 nM HGF/NK4 plus 30 nM HGF/beta (F and H). Bars represent 200 µm in A to F and 100 µm in G and H, respectively.

Induction of c-Met Tyrosine Phosphorylation-- Multiple biological activities of HGF depend on tyrosine phosphorylation of c-Met/HGF receptor upon HGF binding. We next analyzed tyrosine phosphorylation of c-Met/HGF receptor in A549 cells (Fig. 5). Tyrosine phosphorylation of c-Met/HGF receptor was not seen in nonstimulated cells, but addition of HGF induced tyrosine phosphorylation of the c-Met/HGF receptor. Neither 1.5 nM HGF/NK4 alone nor 30 nM HGF/beta alone induced tyrosine phosphorylation; however, a combination of HGF/NK4 plus HGF/beta dose-dependently induced tyrosine phosphorylation of the receptor. The tyrosine phosphorylation seen with 1.5 nM HGF/NK4 plus 30 nM HGF/beta was slightly lower than that seen with 100 pM HGF. Taken together, biological activities of HGF/NK4, HGF/beta , and their combination seem to depend on their potential to induce tyrosine phosphorylation of the c-Met/HGF receptor.


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 5.   Effects of HGF/NK4, HGF/beta , and their combinations on tyrosine autophosphorylation of the c-Met/HGF receptor. A549 cells were cultured to subconfluency, then serum-starved for 20 h. HGF/NK4 (1.5 nM), HGF/beta (30 nM), HGF/NK4 (1.5 nM) plus HGF/beta (3 nM), HGF/NK4 (1.5 nM) plus HGF/beta (30 nM), or HGF (0.1 nM) was added to the cultures, and cells were extracted 10 min later. The c-Met/HGF receptor was immunoprecipitated and subjected to SDS-PAGE under reducing conditions. Proteins were electroblotted onto a polyvinylidene difluoride membrane and probed with anti-c-Met antibody or anti-phosphotyrosine (anti-P-Tyr) antibody. IB, immunoblotting.

Specific Binding of HGF/beta to the Receptor-- Based on above results, we considered that although HGF/beta alone does not bind to the c-Met/HGF receptor, HGF/beta might specifically bind to the receptor in the presence of HGF/NK4. To test this hypothesis, we analyzed concentration-dependent binding of radiolabeled HGF and HGF/beta to HuCC-T1 cells (Fig. 6). Scatchard analysis of concentration-dependent binding of 125I-HGF up to 60 pM resulted in a rectilinear plot (Fig. 6A, inset). The Kd value and the number of HGF receptors were calculated to be 36 pM and 2728 sites/cell, respectively. Our previous study demonstrated that 125I-HGF and 125I-HGF/NK4, respectively, bind to the receptor on rat liver plasma membranes with a Kd values of 64.5 pM and 486 pM (32), indicating that HGF/NK4 binds to the receptor with 8-fold lower affinity than that of HGF. The value seems to be fairly consistent with the result of the competitive binding (Fig. 1). On the other hand, Scatchard analysis on 125I-HGF/beta binding indicated that the Kd value and the number of binding sites were 14455 pM and 18042 sites/cell, respectively (Fig. 6B). The abundant binding sites and the very low affinity suggest that 125I-HGF/beta alone seems to bind nonspecifically to sites clearly distinct from the c-Met/HGF receptor. However, in the presence of 1.5 nM HGF/NK4, 125I-HGF/beta specifically bound to the cells with a higher affinity than that without HGF/NK4; the Kd value and the number of binding sites were 2449 pM and 3394 sites/cell, respectively (Fig. 6C). Although the affinity of HGF/beta to the binding sites in the presence of HGF/NK4 was still 68-fold lower than that of HGF, the Kd value of 2449 pM seems to coincide with a biologically effective concentration for its half-maximal activity (approximately 3 nM) in the presence of HGF/NK4 and the number of binding sites is fairly close to that for HGF. Together with previous results that HGF/beta induces tyrosine phosphorylation of c-Met/HGF receptor and subsequent biological responses which specifically occur in the presence of HGF/NK4, these present results strongly suggest that HGF/beta specifically binds to the c-Met/HGF receptor in the presence of HGF/NK4.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 6.   Concentration-dependent binding of radiolabeled HGF (A) and HGF/beta (B and C) to HuCC-T1 cells. The binding of HGF/beta was examined in the absence (B) or presence (C) of 1.5 nM HGF/NK4. Specific binding to the cells was determined by subtracting nonspecific binding (the binding of 125I-HGF or 125I-HGF/beta in the presence of 200 times excess molar unlabeled ligand) from total binding. Insets show Scatchard plots of each binding. Each value represents the mean of quadruplicate measurements.

To test our hypothesis, we carried out affinity cross-linking experiments using HuCC-T1 cells (Fig. 7). The cells were incubated with radiolabeled ligand and a cross-linker was added. Cell lysate was immunoprecipitated with anti-c-Met antibody and the immunoprecipitate was subjected to SDS-PAGE. When 125I-HGF was cross-linked, radiolabeled cross-linked complexes with molecular masses of 300-500 kDa were immunoprecipitated with anti-c-Met antibody. Radiolabeled complexes with a molecular mass ~300 kDa may be a cross-linked product between HGF (85 kDa) and c-Met/HGF receptor (200 kDa), while complexes with a molecular mass over 400 kDa may be attributable to complexes between HGF and the dimerized c-Met/HGF receptor. Radiolabeled cross-linked products were not formed in the presence of an excess amount of unlabeled HGF, but the formation of cross-linked products was not affected in the presence of an excess amount of unlabeled TGF-alpha . These results indicate that the cross-linked products were specifically formed between c-Met/HGF receptor and 125I-HGF.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 7.   Affinity cross-linking of radiolabeled HGF, HGF/NK4, and HGF/beta to c-Met/HGF receptor in HuCC-T1 cells. In the cases of 125I-HGF and 125I-HGF/NK4, HuCC-T1 cells were affinity-labeled with 125I-HGF or 125I-HGF/NK4 and bis(sulfosuccinimidyl) suberate. In case of 125I-HGF/beta , the cells were affinity-labeled with 125I-HGF/beta and bis(sulfosuccinimidyl) suberate in the presence or absence of HGF/NK4 or HGF/NK2. After affinity-labeling, the cell extract was immunoprecipitated with anti-c-Met receptor antibody, and the immunoprecipitates were subjected to SDS-PAGE under nonreducing conditions. Concentrations of radiolabeled and unlabeled ligands were as follows: 125I-HGF, 40 pM; 125I-HGF/NK4, 0.25 nM; 125I-HGF/beta , 2.5 nM; HGF, 20 nM; TGF-alpha , 20 nM; HGF/NK4 for the binding of 125I-HGF/NK4, 25 nM; HGF/NK4 for the binding of 125I-HGF/beta , 0.5 nM; HGF/NK2, 5 nM; HGF/beta , 500 nM.

When 125I-HGF/NK4 was used, radiolabeled complexes with molecular masses of 300-500 kDa were specifically immunoprecipitated by anti-c-Met antibody. The formation of cross-linked complexes was competitively inhibited by the addition of excess amount of unlabeled HGF/NK4 or HGF, but was not affected by TGF-alpha . Thus, HGF/NK4 alone can specifically bind to the c-Met/HGF receptor. In contrast, when 125I-HGF/beta was added alone, it was not cross-linked with the c-Met/HGF receptor, indicating that HGF/beta alone does not bind to c-Met/HGF receptor. However, when 125I-HGF/beta was added in the presence of 0.5 nM HGF/NK4, 125I-HGF/beta was specifically immunoprecipitated by anti-c-Met antibody, as a complex with a molecular mass of over 300-500 kDa. The formation of cross-linked complexes was competitively inhibited by the addition of an excess amount of unlabeled HGF, as well as HGF/beta , indicating that HGF/beta binds to the c-Met/HGF receptor in the presence of HGF/NK4, but it is competitively inhibited HGF. On the other hand, 125I-HGF/beta scarcely cross-linked with the c-Met/HGF receptor in the presence of HGF/NK2. Therefore, HGF/beta forms a complex with c-Met/HGF receptor in the presence of HGF/NK4, but not HGF/NK2.

HGF/beta Binds and Activates c-Met/HGF Receptor Occupied by HGF/NK4-- Based on these results, we hypothesized that HGF/NK4 binds and occupies the c-Met/HGF receptor, and subsequently, HGF/beta binds to the c-Met/HGF receptor that is occupied with HGF/NK4. To examine this hypothesis, we analyzed tyrosine phosphorylation of c-Met/HGF receptor, under the following conditions: 1) A549 cells were first incubated with 1.5 nM HGF/NK4 at 4 °C for 1 h and washed three times with culture medium to remove unbound free HGF/NK4, and then HGF/beta was added and the cells were incubated at 37 °C for 20 min; and 2) inversely, the cells were first incubated with 30 nM HGF/beta , washed three times, and then HGF/NK4 was added (Fig. 8).


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 8.   Effect of successive treatment with HGF/NK4, HGF/beta , and their combinations on tyrosine phosphorylation of the c-Met/HGF receptor. Serum-starved A549 cells were pretreated with or without 0.1 nM HGF, 1.5 nM HGF/NK4, 30 nM HGF/beta or 0.1 nM HGF at 4 °C for 1 h and washed 3 times with serum-free culture medium to remove unbound ligands. Cells were subsequently treated with or without 1.5 nM HGF/NK4, 30 nM HGF/beta , 1.5 nM HGF/NK4 plus 30 nM HGF/beta , or 0.1 nM HGF at 37 °C for 10 min. The c-Met receptor was immunoprecipitated and subjected to SDS-PAGE. IB, immunoblotting. It should be emphasized that a combination of pretreatment with HGF/NK4 and subsequent treatment with HGF/beta induced tyrosine phosphorylation of the c-Met/HGF receptor, but a combination of pretreatment with HGF/beta and subsequent treatment with HGF/NK4 did not. NK4, HGF/NK4; beta , HGF/beta .

When the cells were first pretreated with HGF/beta and subsequently with HGF/NK4, the c-Met/HGF receptor was not tyrosine-phosphorylated (Fig. 8). Likewise, neither pretreatment nor treatment with HGF/NK4 alone induced tyrosine phosphorylation of the receptor. In contrast, when the cells were pretreated with HGF/NK4 and subsequently treated with HGF/beta , this sequential treatment induced tyrosine phosphorylation of the c-Met/HGF receptor (Fig. 8). The addition of HGF in pretreatment or subsequent treatment induced tyrosine phosphorylation of the receptor. Taken together, we conclude that HGF/beta binds and activates the c-Met/HGF receptor occupied by HGF/NK4, rather than that HGF/beta complexes with HGF/NK4 and subsequently binds and activates the c-Met/HGF receptor.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The unique structural characteristics of HGF as a multipotent growth factor suggested to us that a specific domain is likely responsible for binding to the c-Met/HGF receptor and/or selective biological activity, i.e. mitogenic, motogenic, or morphogenic activity of HGF. On the other hand, biological activities of HGF are mediated through the c-Met/HGF receptor, which integrates complex intracellular signal transduction pathways. The ligand binding to the c-Met/HGF receptor evokes phosphorylation of tyrosine residues located in the kinase domain, the event up-regulates tyrosine kinase activity, and tyrosine phosphorylation in C-terminal tyrosine residues, so-called multiple docking sites, gathers intracellular signaling molecules (35-37). How each domain or subunit in the HGF molecule is involved in activation of the c-Met/HGF receptor upon HGF binding is virtually unknown; however, a specific domain or subunit is likely to regulate a distinct event, such as receptor binding, receptor oligomerization, and tyrosine phosphorylation. We obtained evidence that supports a cooperative mechanism of alpha - and beta -chains of HGF for receptor binding and the subsequent activation, as follows: 1) HGF/NK4 alone binds to the c-Met/HGF receptor, but does not induce tyrosine-phosphorylation of the receptor or elicit biological activities; 2) HGF/beta alone does not bind to the receptor but does bind to the receptor when the receptor is occupied by HGF/NK4, induces tyrosine phosphorylation of the receptor, and exerts mitogenic, motogenic and morphogenic activities; 3) K3 and/or K4 in HGF/NK4 are required for the binding of HGF/beta to the complex of HGF/NK4 and c-Met/HGF receptor.

Previous studies indicate that HGF/NK2 binds to the c-Met/HGF receptor, weakly induces tyrosine phosphorylation, and exerts motogenic activity (23, 25-27, 38). HGF/NK2 has no apparent mitogenic activity in several types of cells, including hepatocytes and endothelial cells (23, 25, 26, 38) (this study), while it has an apparent mitogenic activity in some types of cells (39). Silvagno et al. (38) reported that HGF/NK3 also has no mitogenic activity but has motogenic activity in endothelial cells. In contrast, HGF/NK4 does not induce tyrosine phosphorylation and has no apparent biological activities, even though it does bind to the receptor. We consider that K4 in HGF/NK4 does not block the specific binding between HGF/NK2 or HGF/NK3 and the c-Met/HGF receptor, but may suppress the motogenic activity of HGF/NK2 or HGF/NK3 by suppressing weak tyrosine phosphorylation of the receptor. One possible explanation for the discrepancy in biological activity of HGF/NK2 or HGF/NK3 and HGF/NK4 is that HGF/NK2 or HGF/NK3 may allow for partial or residual activation of the c-Met/HGF receptor and thus partial or low level signaling, leading to cell scattering, but it may not allow for efficient or optimal signaling, leading to cell proliferation and tubule formation. In contrast, the existence of K4 in HGF/NK4 may induce a conformational change in the c-Met/HGF receptor or inhibit receptor dimerization, such that tyrosine autophosphorylation would be mostly impaired. Our results also demonstrated the importance of K3 and/or K4 in the cooperative interaction among HGF/NK4, HGF/beta , and the c-Met/HGF receptor, which occurs on the cell surface c-Met/HGF receptor. HGF/beta did not induce the mitogenic response nor did it form a cross-linked complex with the c-Met/HGF receptor in combination with HGF/NK2. Therefore, the N-terminal hairpin structure and subsequent two kringle domains (K1 and K2) are a specific motif for the high affinity binding of HGF and HGF/NK4 to c-Met/HGF receptor, while K3 and/or K4 in HGF/NK4 are essential for exposing the specific binding site of HGF/beta on the c-Met/HGF receptor occupied by HGF/NK4. In this context, it is noteworthy that the beta -chain alone of HGF-like protein/macrophage-stimulating protein, a family molecule of HGF, directly binds to its receptor, Ron (40). It is interesting to assume that HGF/beta also has a putative binding motif to c-Met/HGF receptor, but in the case of HGF/beta , the binding of HGF/beta depends on the preoccupation of c-Met/HGF receptor with HGF/NK4.

HGF/NK2 elicits motogenic activity, but competitively antagonizes the mitogenic activity of HGF (23, 25, 26). Together with our earlier finding that HGF with K3 or K4 deleted still sustains significant mitogenic activity (30, 31), the importance of the beta -chain for the optimal activation of c-Met/HGF receptor has been equivocally considered. Of particular importance in our present results is that, although HGF/beta itself does not play a role in a specific recognition processes between HGF and the c-Met/HGF receptor, HGF/beta is an indispensable domain for the optimum activation and subsequent activation of intracellular signal transduction pathways that lead to mitogenic, motogenic, and morphogenic responses. How does HGF/beta induce tyrosine phosphorylation of the c-Met/HGF receptor and activate mitogenic, motogenic, and morphogenic responses? Schwall et al. (39) reported that heparin dimerizes HGF/NK1 and confers mitogenic activity, suggesting that heparin-induced dimerization of HGF/NK1 in turn may facilitate dimerization and activation of c-Met/HGF receptor. One possible role of HGF/beta is likely to be that HGF/beta may facilitate dimerization of the receptor, through inducing dimerization and/or stabilization of the ligand. Donate et al. (41) implicated the possibility of HGF to form a noncovalently linked homodimer, through putative interactions between K2 and K3 and/or HGF/beta of each HGF molecule. However, we could not detect HGF/beta -dependent dimerization or oligomerization of c-Met/HGF receptor in our affinity cross-linking experiment (Fig. 7). On the other hand, given that the c-Met/HGF receptor exists in a preassociated form, one possible explanation for the role of HGF/beta is that the binding of HGF/beta to c-Met/HGF receptor occupied with HGF/NK4 can induce the allosteric conformational change required for activation of tyrosine kinase. Which mechanism is involved in activation of the c-Met/HGF receptor should be further analyzed; however, the separation of the two distinct biochemical events, i.e. receptor binding and receptor activation, through utilizing HGF/NK4 and HGF/beta would provide insights into the initial mechanism involved in activation of c-Met/HGF receptor.

In conclusion, we here show that, although HGF/beta alone cannot bind to c-Met/HGF receptor, HGF/beta can bind to the c-Met/HGF receptor occupied with HGF/NK4 and that the binding of HGF/beta induces tyrosine phosphorylation of the receptor and subsequent mitogenic, motogenic, and morphogenic responses in cells. Clearly, the alpha - and beta -chains of HGF have distinct functions. The N-terminal hairpin- and kringle-containing alpha -chain is a motif which specifies high affinity binding to the c-Met/HGF receptor, while the beta -chain seems to play a role in optimal activation of the c-Met/HGF receptor, which enables mitogenic, motogenic, and morphogenic actions of HGF.

    ACKNOWLEDGEMENTS

We are grateful to M. Ohara for translation assistance and to M. Eguchi and K. Bessho for technical assistance.

    FOOTNOTES

* This study was supported by a Research Grant for Science and Cancer from the Ministry of Education, Science, Sports, and Culture of Japan, and grants from Sagawa Cancer Research Foundation, the Ryoichi Naito Foundation for Medical Research, Kudo Foundation, and Tanabe Medical Science Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 81-6-879-3783; Fax: 81-6-879-3789; E-mail: nakamura{at}onbich.med.osaka-u.ac.jp.

The abbreviations used are: HGF, hepatocyte growth factor; TGF-alpha , transforming growth factor-alpha ; PAGE, polyacrylamide gel electrophoresis; HPLC, high performance liquid chromatography; MDCK, Madin-Darby canine kidney cells.

2 K. Matsumoto, H. Kataoka, K. Date, and T. Nakamura, unpublished observation.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Zarnegar, R., and Michalopoulos, G. K. (1995) J. Cell Biol. 129, 1177-1180[Free Full Text]
  2. Boros, P., and Miller, C. M. (1995) Lancet 345, 293-295[CrossRef][Medline] [Order article via Infotrieve]
  3. Matsumoto, K., and Nakamura, T. (1997) Biochem. Biophys. Res. Commun. 239, 639-644[CrossRef][Medline] [Order article via Infotrieve]
  4. Bussolino, F., Di Renzo, M. F., Ziche, M., Bochietto, E., Olivero, M., Naldini, L., Gaudino, G., Tamagnone, L., Coffer, A., and Comoglio, P. M. (1992) J. Cell Biol. 119, 629-641[Abstract/Free Full Text]
  5. Grant, D. S., Kleinman, H. K., Goldberg, I. D., Bhargava, M. M., Nickoloff, B. J., Kinsella, J. I., Polverini, P., and Rosen, E. M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 1937-1941[Abstract/Free Full Text]
  6. Grano, M., Galimi, F., Zambonin, G., Colucci, S., Cottone, E., Zallone, A. Z., and Comoglio, P. M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7644-7648[Abstract/Free Full Text]
  7. Takebayashi, T., Iwamoto, Y., Jikko, A., Matsumura, T., Enomoto-Iwamoto, M., Myoukai, F., Koyama, E., Yamaai, T., Matsumoto, K., Nakamura, T., Kurisu, K., and Noji, S. (1995) J. Cell Biol. 129, 1411-1419[Abstract/Free Full Text]
  8. Galimi, F., Bagnara, G. P., Bonsi, L., Cottone, E., Follenzi, A., Simeone, A., and Comoglio, P. M. (1994) J. Cell Biol. 127, 1743-1754[Abstract/Free Full Text]
  9. Takai, K., Hara, J., Matsumoto, K., Hosoi, G., Osugi, Y., Tawa, A., Okada, S., and Nakamura, T. (1997) Blood 89, 1560-1565[Abstract/Free Full Text]
  10. Schmidt, C., Bladt, F., Goedecke, S., Brinkmann, V., Zschiesche, W., Sharpe, M., Gherardi, E., and Birchmeier, C. (1995) Nature 373, 699-702[CrossRef][Medline] [Order article via Infotrieve]
  11. Uehara, Y., Minowa, O., Mori, C., Shiota, K., Kuno, J., Noda, T., and Kitamura, N. (1995) Nature 373, 702-705[CrossRef][Medline] [Order article via Infotrieve]
  12. Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A., and Birchmeier, C. (1995) Nature 376, 768-771[CrossRef][Medline] [Order article via Infotrieve]
  13. Maina, F., Casagranda, F., Audero, E., Simeone, A., Comoglio, P. M., Klein, R., and Ponzetto, C. (1996) Cell 87, 531-542[CrossRef][Medline] [Order article via Infotrieve]
  14. Montesano, R., Matsumoto, K., Nakamura, T., and Orci, L. (1991) Cell 67, 901-908[CrossRef][Medline] [Order article via Infotrieve]
  15. Soriano, J. V., Pepper, M. S., Nakamura, T., Orci, L., and Montesano, R. (1995) J. Cell Sci. 108, 413-430[Abstract]
  16. Yang, Y. M., Spitzer, E., Meyer, D., Sachs, M., Niemann, C., Hartmann, G., Weidner, K. M., Birchmeier, C., and Birchmeier, W. (1995) J. Cell Biol. 131, 215-226[Abstract/Free Full Text]
  17. Noji, S., Tashiro, K., Koyama, E., Nohno, T., Ohyama, K., Taniguchi, S., and Nakamura, T. (1990) Biochem. Biophys. Res. Commun. 173, 42-47[CrossRef][Medline] [Order article via Infotrieve]
  18. Sonnenberg, E., Meyer, D., Weidner, K. M., and Birchmeier, C. (1993) J. Cell Biol. 123, 223-235[Abstract/Free Full Text]
  19. Nakamura, T., Nawa, K., Ichihara, A., Kaise, N., and Nishino, T. (1987) FEBS Lett. 224, 311-318[CrossRef][Medline] [Order article via Infotrieve]
  20. Gohda, E., Tsubouchi, H., Nakayama, H., Hirono, S., Sakiyama, O., Takahashi, K., Miyazaki, H., Hashimoto, S., and Dikuhara, Y. (1988) J. Clin. Invest. 81, 414-419
  21. Zarnegar, R., and Michalopoulos, G. K. (1989) Cancer Res. 49, 3314-3320[Abstract/Free Full Text]
  22. Nakamura, T., Nishizawa, T., Hagiya, M., Seki, T., Shimonishi, M., Sugimura, A., Tashiro, K., and Shimizu, S. (1989) Nature 342, 440-443[CrossRef][Medline] [Order article via Infotrieve]
  23. Chan, A. M.-L., Rubin, J. S., Bottaro, D. P., Hirschfield, D. W., Chedid, M., and Aaronson, S. A. (1991) Science 254, 1382-1385[Abstract/Free Full Text]
  24. Miyazawa, K., Kitamura, A., Naka, D., and Kitamura, N. (1991) Eur. J. Biochem. 197, 15-22[Medline] [Order article via Infotrieve]
  25. Hartmann, G., Naldini, L., Weidner, K. M., Sachs, M., Vigna, E., Comoglio, P. M., and Birchmeier, W. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 11574-11578[Abstract/Free Full Text]
  26. Lokker, N. A., Mark, M. R., Luis, E. A., Bennett, G. L., K., Robbins, K. A., Baker, J. B., and Godowski, P. J. (1992) EMBO J. 11, 2503-2510[Medline] [Order article via Infotrieve]
  27. Itakura, Y., Yamamoto, T., Matsumoto, K., and Nakamura, T. (1994) Cancer Lett. 83, 235-243[CrossRef][Medline] [Order article via Infotrieve]
  28. Lokker, N. A., and Godowski, P. J. (1993) J. Biol. Chem. 268, 17145-17150[Abstract/Free Full Text]
  29. Cioce, V., Csaky, K. G., Chan, A. M.-L., Bottaro, D. P., Taylor, W. G., Jensen, R., Aaronson, S. A., and Rubin, J. S. (1996) J. Biol. Chem. 271, 13110-13115[Abstract/Free Full Text]
  30. Matsumoto, K., Takehara, T., Inoue, H., Hagiya, M., Shimizu, S., and Nakamura, T. (1991) Biochem. Biophys. Res. Commun. 181, 691-699[CrossRef][Medline] [Order article via Infotrieve]
  31. Okigaki, M., Komada, M., Uehara, Y., Miyazawa, K., and Kitamura, N. (1992) Biochemistry 31, 9555-9561[CrossRef][Medline] [Order article via Infotrieve]
  32. Date, K., Matsumoto, K., Shimura, H., Tanaka, M., and Nakamura, T. (1997) FEBS Lett. 420, 1-6[CrossRef][Medline] [Order article via Infotrieve]
  33. Seki, T., Ihara, I., Sugimura, A., Shimonishi, M., Nishizawa, T., Asami, O., Hagiya, M., Nakamura, T., and Shimizu, S. (1990) Biochem. Biophys. Res. Commun. 172, 321-327[CrossRef][Medline] [Order article via Infotrieve]
  34. Yamada, A., Matsumoto, K., Iwanari, H., Sekiguchi, K., Kawata, S., Matsuzawa, Y., and Nakamura, T. (1995) Biomed. Res. 16, 105-114
  35. Ponzetto, C., Bardelli, A., Zhen, Z., Maina, F., Zonca, P., Giordano, Graziani, S. A., Panayotou, G., and Comoglio, P. M. (1994) Cell 77, 261-271[CrossRef][Medline] [Order article via Infotrieve]
  36. Zhu, H., Naujokas, M. A., Fixman, E. D., Torossian, K., and Park, M. (1994) J. Biol. Chem. 269, 29943-29948[Abstract/Free Full Text]
  37. Weidner, K. M., Sachs, M., Riethmacher, D., and Birchmeier, W. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 2597-2601[Abstract/Free Full Text]
  38. Silvagno, F., Follenzi, A., Arese, M., Prat, M., Giraudo, E., Gaudino, G., Camussi, G., Comoglio, P. M., and Bussolino, F. (1995) Arterioscler. Thromb. Vasc. Biol. 15, 1857-1865[Abstract/Free Full Text]
  39. Schwall, R., Chang, L. Y., Godowski, P. J., Kahn, D. W., Hillan, K. J., Bauer, K. D., and Zioncheck, T. F. (1996) J. Cell Biol. 133, 709-718[Abstract/Free Full Text]
  40. Wang, M.-H., Julian, F. M., Breathnach, R., Godowski, P. J., Takehara, T., Yoshikawa, W., Hagiya, M., and Leonard, E. J. (1997) J. Biol. Chem. 272, 16999-17004[Abstract/Free Full Text]
  41. Donate, L. E., Gherardi, E., Srinivasan, N., Sowdhamini, R., Aparicio, S., and Blundel, T. L. (1994) Protein Sci. 3, 2378-2394[Abstract]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
W. W. Raymond, A. C. Cruz, and G. H. Caughey
Mast Cell and Neutrophil Peptidases Attack an Inactivation Segment in Hepatocyte Growth Factor to Generate NK4-like Antagonists
J. Biol. Chem., January 20, 2006; 281(3): 1489 - 1494.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Kirchhofer, X. Yao, M. Peek, C. Eigenbrot, M. T. Lipari, K. L. Billeci, H. R. Maun, P. Moran, L. Santell, C. Wiesmann, et al.
Structural and Functional Basis of the Serine Protease-like Hepatocyte Growth Factor {beta}-Chain in Met Binding and Signaling
J. Biol. Chem., September 17, 2004; 279(38): 39915 - 39924.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
T. A. Martin, C. Parr, G. Davies, G. Watkins, J. Lane, K. Matsumoto, T. Nakamura, R. E. Mansel, and W. G. Jiang
Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist
Carcinogenesis, August 1, 2003; 24(8): 1317 - 1323.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Saimura, E. Nagai, K. Mizumoto, N. Maehara, Y. A. Minamishima, M. Katano, K. Matsumoto, T. Nakamura, and M. Tanaka
Tumor Suppression through Angiogenesis Inhibition by SUIT-2 Pancreatic Cancer Cells Genetically Engineered to Secrete NK4
Clin. Cancer Res., October 1, 2002; 8(10): 3243 - 3249.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
F. LIU, K. L. SCHAPHORST, A. D. VERIN, K. JACOBS, A. BIRUKOVA, R. M. DAY, N. BOGATCHEVA, D. P. BOTTARO, and J. G. N. GARCIA
Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase-3{beta}
FASEB J, July 1, 2002; 16(9): 950 - 962.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
W. G. Jiang, D. Grimshaw, J. Lane, T. A. Martin, R. Abounder, J. Laterra, and R. E. Mansel
A Hammerhead Ribozyme Suppresses Expression of Hepatocyte Growth Factor/Scatter Factor Receptor c-MET and Reduces Migration and Invasiveness of Breast Cancer Cells
Clin. Cancer Res., August 1, 2001; 7(8): 2555 - 2562.
[Abstract] [Full Text] [PDF]


Home page